Palo Alto – September 1, 2016 – Cooley advised Eiger Biopharmaceuticals on its $20 million shelf-takedown of 1,250,000 shares of common stock.
Eiger, which trades on The NASDAQ Global Market as "EIGR," is a clinical stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of orphan diseases.
Jefferies acted as sole book-running manager for the offering. Oppenheimer & Co. and Wedbush PacGrow acted as co-managers.
Earlier this year, Cooley also advised Eiger on its agreement to merge with Celladon.
The Cooley corporate securities team advising Eiger included Glen Sato, Mike Tenta, Peter Mandel, Lara Mouritsen and Allison Peth.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.